OLN Olin (OLN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0000074303
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
217
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · no price filed
What the filings say about OLN
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-14
Olin insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for OLIN Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1820.7% of the 357 shares held after it.
- 3 other insiders sold within 30 days.
- 217 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP & President CAPV Carter Deon sold about $154.2K of OLN on Feb 25, 2026; 3 other insiders sold within 30 days and 217 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 155.7% of the 1,527 shares held after it.
- 3 other insiders sold within 30 days.
- 217 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP & Chief Legal Officer Castle Angela M sold about $57.7K of OLN on Feb 24, 2026; 3 other insiders sold within 30 days and 217 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 8, 2024.
- The trade is 19.2% of the 24,771 shares held after it.
- 3 other insiders sold within 30 days.
- 217 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP & Controller Sumner R Nichole sold about $106.8K of OLN on Feb 3, 2026; 3 other insiders sold within 30 days and 217 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jan 30, 2024.
- The trade is 208.3% of the 44,291 shares held after it.
- 3 other insiders sold within 30 days.
- 217 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP & CFO Slater Todd A sold about $2.1M of OLN on Feb 3, 2026, the largest insider sale at the company since 2024; 3 other insiders sold within 30 days and 217 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 13, 2025.
- The trade is 26.2% of the 17,199 shares held after it.
- No other insider sold within 30 days.
- 217 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP & Treasurer VERMILLION TERESA M sold about $93.9K of OLN on Nov 26, 2025; 217 funds added in the latest 13F quarter.78 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
217 funds bought in last quarter
more than 91% of Pharma & Biotech
Revenue
+3.7% year over year
more than 51% of Pharma & Biotech
Margin
-1.5% net margin
more than 72% of Pharma & Biotech
Buybacks
$50.5M repurchased, FY to 2025-12-31
more than 57% of Pharma & Biotech
Short interest
13.2% of the float short (float per yahoo 2026-10-26) · 5.2 days to cover · settled 2026-09-30
more than 79% of Pharma & Biotech
What changed in the last 30 days
Oct 12Rep. Lisa McClain sold $15K to $50K, disclosed 28 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch OLN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-31.9%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns OLN: institutional holders (13F)
13F holdings, latest reported quarter
16,021,214 sh
$317.5M
11,984,254 sh
$237.5M
6,166,477 sh
$122.2M
5,510,335 sh
$109.2M
5,447,478 sh
$108.0M
Congress trades in OLN
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-14 · disclosed 28 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
OLN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
OLN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
HW Opportunities MP Fund
$5.0M position · as of 2026-06-30
6.2%
Hotchkis and Wiley Small Cap Value Fund
$29.8M position · as of 2026-06-30
3.7%
Hotchkis & Wiley Opportunities Fund
$26.0M position · as of 2026-06-30
2.9%
The Acquirers Fund
$862.5K position · as of 2026-07-31
2.7%
First Trust Materials AlphaDEX Fund
$8.8M position · as of 2026-07-31
2.4%
Hotchkis and Wiley Mid-Cap Value Fund
$8.0M position · as of 2026-06-30
2.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Defense
THE PURPOSE OF THIS DELIVERY ORDER IS TO AWARD THE XM1201 ONE-WAY LUMINESCENT (OWL) TRACER MANUFACTU · 2021-03-29
$356.4M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Scott MSutton
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$12.0M
$13.5M
$2.3M
+130%
+28%
2022
$10.7M
$8.9M
$2.4M
+123%
+10%
2021
$10.1M
$41.2M
$3.2M
+139%
+17%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 217 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
OLN financials
Revenue growth
+3.7%
XBRL, annual
Net margin
-1.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.7B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM OLN
| FY Dec 2025 | $6.8B |
| FY Dec 2024 | $6.5B |
| FY Dec 2023 | $6.8B |
| FY Dec 2022 | $9.4B |
| FY Dec 2021 | $8.9B |
| Jun 2026 | $1.7B |
| Mar 2026 | $1.6B |
| Dec 2025 | $1.7B |
| Sep 2025 | $1.7B |
| Jun 2025 | $1.8B |
| Mar 2025 | $1.6B |
| Dec 2024 | $1.7B |
| Sep 2024 | $1.6B |
At each fiscal year end
Single quarter
Net margin, TTM
-2.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM OLN
| FY Dec 2025 | -1.5% |
| FY Dec 2024 | +1.6% |
| FY Dec 2023 | +6.6% |
| FY Dec 2022 | +14.2% |
| FY Dec 2021 | +14.6% |
| Jun 2026 | -0.8% |
| Mar 2026 | -5.2% |
| Dec 2025 | -8.6% |
| Sep 2025 | +2.6% |
| Jun 2025 | -0.2% |
| Mar 2025 | +0.1% |
| Dec 2024 | +0.6% |
| Sep 2024 | -1.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$100.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM OLN
| FY Dec 2025 | $247.9M |
| FY Dec 2024 | $308.1M |
| FY Dec 2023 | $738.3M |
| FY Dec 2022 | $1.7B |
| FY Dec 2021 | $1.5B |
| Jun 2026 | -$21.1M |
| Mar 2026 | -$92.3M |
| Dec 2025 | $258.4M |
| Sep 2025 | -$44.4M |
| Jun 2025 | $181.3M |
| Mar 2025 | -$147.4M |
| Dec 2024 | $90.7M |
| Sep 2024 | $146.6M |
At each fiscal year end
Single quarter
Debt to equity
1.77x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity OLN
| FY Dec 2025 | 1.54x |
| FY Dec 2024 | 1.40x |
| FY Dec 2023 | 1.20x |
| FY Dec 2022 | 1.01x |
| FY Dec 2021 | 1.05x |
| Jun 2026 | 1.77x |
| Mar 2026 | 1.73x |
| Dec 2025 | 1.54x |
| Sep 2025 | 1.53x |
| Jun 2025 | 1.53x |
| Mar 2025 | 1.51x |
| Dec 2024 | 1.40x |
| Sep 2024 | 1.40x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.10x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt OLN
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | 0.18x |
| FY Dec 2023 | 0.36x |
| FY Dec 2022 | 0.74x |
| FY Dec 2021 | 0.63x |
| Jun 2026 | 0.10x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.10x |
| Jun 2025 | 0.15x |
| Mar 2025 | 0.11x |
| Dec 2024 | 0.18x |
| Sep 2024 | 0.27x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-10.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity OLN
| FY Dec 2025 | -5.2% |
| FY Dec 2024 | +4.9% |
| FY Dec 2023 | +18.9% |
| FY Dec 2022 | +51.1% |
| FY Dec 2021 | +63.2% |
| Jun 2026 | -10.7% |
| Mar 2026 | -9.9% |
| Dec 2025 | -5.2% |
| Sep 2025 | +2.6% |
| Jun 2025 | -0.8% |
| Mar 2025 | +2.8% |
| Dec 2024 | +4.9% |
| Sep 2024 | +6.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-2.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets OLN
| FY Dec 2025 | -1.4% |
| FY Dec 2024 | +1.4% |
| FY Dec 2023 | +5.7% |
| FY Dec 2022 | +16.0% |
| FY Dec 2021 | +15.4% |
| Jun 2026 | -2.6% |
| Mar 2026 | -2.5% |
| Dec 2025 | -1.4% |
| Sep 2025 | +0.7% |
| Jun 2025 | -0.2% |
| Mar 2025 | +0.8% |
| Dec 2024 | +1.4% |
| Sep 2024 | +1.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital OLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | +4.6% |
| FY Dec 2023 | +11.8% |
| FY Dec 2022 | +28.2% |
| FY Dec 2021 | +33.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | +3.4% |
| Dec 2024 | +4.6% |
| Sep 2024 | +5.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed OLN
| FY Dec 2025 | +0.1% |
| FY Dec 2024 | +4.9% |
| FY Dec 2023 | +11.2% |
| FY Dec 2022 | +26.7% |
| FY Dec 2021 | +26.6% |
| Jun 2026 | -1.8% |
| Mar 2026 | -1.9% |
| Dec 2025 | +0.1% |
| Sep 2025 | +3.4% |
| Jun 2025 | +2.3% |
| Mar 2025 | +3.9% |
| Dec 2024 | +4.9% |
| Sep 2024 | +5.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing OLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | 37.14x |
| FY Dec 2023 | 15.15x |
| FY Dec 2022 | 5.93x |
| FY Dec 2021 | 7.24x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 53.17x |
| Jun 2025 | n/a |
| Mar 2025 | 46.62x |
| Dec 2024 | 37.14x |
| Sep 2024 | 38.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.7B
market value at close 2026-10-26 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2025-12-31
Enterprise value OLN
| FY Dec 2025 | $5.0B |
| FY Dec 2024 | $6.6B |
| FY Dec 2023 | $9.1B |
| FY Dec 2022 | $9.6B |
| FY Dec 2021 | $11.8B |
| Jun 2026 | $5.1B |
| Mar 2026 | $6.2B |
| Dec 2025 | $5.0B |
| Sep 2025 | $5.7B |
| Jun 2025 | $5.1B |
| Mar 2025 | $5.7B |
| Dec 2024 | $6.6B |
| Sep 2024 | $8.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield OLN
| FY Dec 2025 | +10.4% |
| FY Dec 2024 | +7.8% |
| FY Dec 2023 | +11.2% |
| FY Dec 2022 | +23.2% |
| FY Dec 2021 | +16.8% |
| Jun 2026 | +4.5% |
| Mar 2026 | +8.9% |
| Dec 2025 | +10.4% |
| Sep 2025 | +2.8% |
| Jun 2025 | +11.8% |
| Mar 2025 | +4.4% |
| Dec 2024 | +7.8% |
| Sep 2024 | +10.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing OLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.49x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $6.8B | $6.5B | $6.8B | $9.4B |
| Gross profit | $501.5M | $737.5M | $1.2B | $2.2B |
| Operating income | $5.3M | $296.5M | $712.1M | $1.8B |
| Net income | -$101.1M | $105.0M | $452.0M | $1.3B |
| EPS (diluted) | -0.88 | 0.91 | 3.57 | 8.94 |
| Operating cash flow | $474.2M | $503.2M | $974.3M | $1.9B |
| Cash | $167.6M | $175.6M | $170.3M | $194.0M |
| Long-term debt | $2.7B | $2.7B | $2.6B | $2.6B |
| Buybacks | $50.5M | $300.3M | $711.3M | $1.4B |
| Dividends paid | $91.6M | $94.2M | $101.0M | $116.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
OLN Stock Sonar score 5/7 axes
Find similar shapesCompareOLN ranks highest on profitability (80th percentile) and institutional and government (77th), and lowest on risk and compliance (27th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OLN filings, in plain words
Have members of Congress traded OLN?
Yes. In the year to 2026-10-28, 1 House member disclosed buying OLN and 0 House members disclosed selling it; the latest on record is a purchase by Lisa McClain dated 2026-09-14.
Read the full summary
In the year to 2026-10-28, 1 member of Congress disclosed buying OLN and 0 members disclosed selling it; the latest on record is a purchase by Lisa McClain dated 2026-09-14. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
